News

Coeliac disease affects at least 1 in 100 people in the UK and in Europe,1 and the only way to manage it is through a strict gluten-free diet. However, non-adherence to this diet, whether voluntary or involuntary, is relatively common among coeliac patients, making it challenging for clinicians to determine if other factors are causing symptoms.

Join us for a live webinar on the 20th of January at 1pm, hosted by Ángel Cebolla Ramirez, CEO of Biomedal SL. Ángel will talk about the importance of testing for gluten-free diet adherence using Gluten Immunogenic Peptide (GIP) Tests. These tests detect GIPs in urine or stool to determine whether someone has recently consumed gluten. This allows healthcare teams to objectively monitor and improve adherence to a gluten-free diet, and detect ongoing intestinal damage risk.

Register today to secure your place! CLICK HERE

BIOHIT is delighted to announce the appointment of Manraj Singh Ubhi as Regional Sales Manager, supporting the company’s ongoing growth across the West Midlands, Staffordshire, Wales and Merseyside. Manraj will play a key role in promoting BIOHIT’s unique gastroenterological diagnostic solutions and training clinicians on product use to improve patient care.

Join us for a live webinar on the 14^th of May 2025, hosted by Andrew Woodcock, Chief Scientific Officer at RD Biomed. This session will explore Peptest^®, our non-invasive, saliva-based test that uses lateral flow technology to detect pepsin, a key biomarker of gastric reflux.

During the webinar, we’ll take a closer look at the development of Peptest, its clinical utility in helping to diagnose conditions such as laryngopharyngeal reflux (LPR), and its role in primary and specialist care settings. You’ll also gain insight into how this diagnostic tool supports post-treatment monitoring and improves overall patient outcomes.

BIOHIT is excited to announce an agreement with Biomedal to supply its iVYLISA, iVYCHECK and GlutenDetect gluten immunogenic peptide (GIP) tests. Under this agreement, BIOHIT will have exclusive distribution rights over Biomedal’s range of rapid tests and immunoassays for gluten detection in the Czech Republic, Denmark, Finland, France, Hungary, Ireland, the Netherlands, Norway, Portugal, Sweden, Switzerland and the UK. BIOHIT will also have non-exclusive rights in all other European countries, excluding Italy and Spain.

BIOHIT HealthCare is pleased to announce that a clinical study conducted by Homerton University Hospital NHS Foundation Trust, London, has confirmed the diagnostic accuracy of GastroPanel in identifying gastric cancer risk in patients with upper abdominal complaints. This study demonstrated that the panel can reliably identify patients at high risk of gastric cancer with over 90 % accuracy, helping to streamline patient management.

BIOHIT OYJ is proud to announce that its GastroPanel Quick Test NT has been nominated as the best new clinical diagnostic product in the prestigious SelectScience^® Scientists’ Choice Awards. This nomination celebrates how this breakthrough diagnostic test is transforming gastroscopy workflows by swiftly triaging patients at the point of care.

BIOHIT HealthCare is excited to announce an upcoming webinar on the Current and future trends in inflammatory bowel disease (IBD) therapeutic drug monitoring (TDM), which will take place on the 3^rd of July at 12:30-1:30pm BST. The BIOHIT team will be joined by Rachel Nice, Section Lead for R&D and Specialist Services at Exeter Clinical Laboratory, and Rebecca Smith, Gastroenterology Specialist Registrar, both from the Royal Devon University Healthcare NHS Foundation Trust, to tackle the burning questions around this topical subject.

BIOHIT HealthCare is attending BSG LIVE’24 at ICC Birmingham from the 17^th to the 20^th of June, where it will be showcasing its broad range of gastrointestinal diagnostic solutions. It will also be hosting a fascinating symposium discussing the use of GastroPanel^® for gastric cancer risk assessment, presented by expert guest speaker, Dr Cinzia Papadia.

BIOHIT HealthCare Ltd are pleased to announce the appointment of Angela Gore as Market Access & Development Manager.

Following a successful few years of growth at BIOHIT, this announcement sees the expansion of the BIOHIT team. This new role will focus on developing networks within the NHS, improving the exposure of BIOHIT’s key products, and broadening the company’s market reach into new areas.

BIOHIT HealthCare is pleased to extend its corporate partnership with the British Laryngological Association (BLA) for a second year running, supporting its pursuit of improved diagnosis for laryngopharyngeal reflux (LPR).

BIOHIT HealthCare is excited to announce its upcoming webinar entitled Proactive vs reactive therapeutic drug monitoring in inflammatory bowel disease (IBD). The event will take place on the 26^th of October at 11 am, and will include a live Q&A with the expert speakers, Professor Jimmy Limdi and Dr Christian Selinger and moderated by The Clinical Services Journal.

BIOHIT is pleased to announce its attendance at IBMS Congress 2023, where it will showcase its new GastroPanel^® Quick Test for triaging gastroscopy referrals. The prestigious annual event promises to be the UK’s largest biomedical science exhibition, and will feature over 300 lectures covering 13 medical disciplines, exploring the latest technological advances, products, services and equipment in the rapidly evolving field of laboratory medicine.

BIOHIT Ltd will be attending the upcoming BSG Live 2023 conference in Liverpool, where it will unveil a revolutionary new test to support decision making for gastroscopy referrals and improve the early detection of gastric cancer. The GastroPanel® Quick Test diagnoses Helicobacter pylori infection, atrophic gastritis (AG) – a precancerous condition – and high gastric acid output in just 15 minutes, helping to triage patients in primary care and promote early discovery and treatment of gastrointestinal disorders.

BIOHIT is excited to launch its GastroPanel Quick Test at BSG LIVE’23, which will take place from the 19th to the 22nd of June at the Arena and Conference Centre (ACC) Liverpool. This annual meeting provides the ideal opportunity to share this innovation with colleagues in the gastroenterology and hepatology community, as they come together to discuss the latest advances in the field.

BIOHIT is pleased to announce its partnership with Celltrion Healthcare UK Ltd, providing point-of-care assays for the Celltrion Connect Dedicated Homecare Service, which is designed to seamlessly support patients with inflammatory bowel disease (IBD) and their healthcare providers. BIOHIT will be supplying the Preventis SmarTest^® Calprotectin Home test – a digital self-test system that combines a faecal calprotectin test with a smartphone app to help patients to monitor their condition in the comfort of their own homes.

BIOHIT is excited to be exhibiting at this year’s British Society for Immunology (BSI) Congress in Liverpool. The UK’s premier immunology event, taking place from the 5th to 8th of December, welcomes over 1,500 attendees – including scientists, researchers and clinical specialists – to witness a fascinating fusion of innovative research from around the world.

Today BIOHIT are pleased to announce they have become the corporate partner of the British Laryngological Association (BLA) for 2022-2023. This partnership brings together two organisations that are striving to achieve advancements in laryngology for the benefit of the patient and healthcare providers.

BIOHIT is pleased to announce that it is now the exclusive UK and Ireland distributor of Preventis GmbH’s SmarTest^® Calprotectin Home, a digital self-test system that combines a faecal calprotectin test with a smartphone app. The innovative product has been designed especially for patients with chronic inflammatory bowel disease (IBD) and allows individuals to routinely self-monitor their disease activity by quantitatively measuring their faecal calprotectin levels at home.

BIOHIT is excited to be exhibiting at the upcoming BSG LIVE ’22 at the ICC in Birmingham. This event, which takes place from the 20^th to 23^rd of June, showcases the latest clinical and educational developments within gastroenterology and hepatology.

BIOHIT is pleased to announce the launch of its new website. This new look and feel is designed to reflect the company’s vision, mission and values, while making it easier than ever for customers and partners to find the information they need. Visitors to the site can now quickly navigate to the disease area or products of interest, and there is also a resource section to provide rapid access to brochures, webinars, case studies and blogs.

A clinical validation study conducted at Oulu University Hospital (OUH) has confirmed the high accuracy of BIOHIT Oyj’s new generation GastroPanel® test for the diagnosis of atrophic gastritis (AG) and Helicobacter pylori (Hp) infection in patients referred for gastroscopy.1 This unique blood test is designed for the first-line diagnosis of Hp infection and AG in patients with upper abdominal symptoms, such as dyspepsia and gastro-oesophageal reflux disease (GORD), before endoscopy. GastroPanel is also the only test on the market capable of monitoring the regulatory mechanism of acid output in the stomach.

BIOHIT Ltd is now distributing three new particle enhanced turbidimetric immunoassays (PETIAs) for the rapid and differential diagnosis of gastrointestinal (GI) diseases.

A recent study published by the research group of Professor Francesco Di Mario at Parma University, Italy, found a strong relationship between low levels of plasma Gastrin-17 (G-17) and the manifestation of gastro-oesophageal reflux disease (GORD).